Back to Browse Journals » Vascular Health and Risk Management » Volume 3 » Issue 6

A review of thiazolidinediones and metformin in the treatment of type 2 diabetes with focus on cardiovascular complications

Authors Behzad Molavi, Negah Rassouli, Suveer Bagwe, Neda Rasouli

Published Date January 2007 Volume 2007:3(6) Pages 967—973

DOI

Published 15 January 2007

Behzad Molavi1, Negah Rassouli2, Suveer Bagwe1, Neda Rasouli2

Central Arkansas Veterans Healthcare System and University of Arkansas for Medical sciences, 1Division of cardiology and 2Division of Endocrinology, College of Medicine, Little Rock, Arkansas, USA

Abstract: The rising incidence of obesity and insulin resistance to epidemic proportions has closely paralleled the surge in the prevalence of diabetes and outpaced therapeutic advances in diabetes prevention and treatment. Current evidence points to obesity induced oxidative stress and chronic inflammation as the common denominators in the evolution of insulin resistance and diabetes. Of all the hypoglycemic agents in the pharmacological arsenal against diabetes, thiazolidinediones, in particular pioglitazone, as well as metformin appear to have additional effects in ameliorating oxidative stress and inflammation; rendering them attractive tools for prevention of insulin resistance and diabetes. In addition to their hypoglycemic and lipid modifying properties, pioglitazone and metformin have been shown to exert anti-oxidative and anti-inflammatory effects in vascular beds, potentially slowing the accelerated atherosclerosis in diabetes, which is the major cause of morbidity and mortality in the affected population. The combination of pioglitazone and metformin would thus appear to be an effective pharmacological intervention in prevention and treatment of diabetes. Finally, this review will address the currently available evidence on diabetic cardiomyopathy and the potential role of combination therapy with pioglitazone and metformin.

Keywords: insulin resistance, oxidative stress, inflammation, pioglitazone, metformin, atherosclerosis, diabetic cardiomyopathy

Download Article [PDF] 

Readers of this article also read:

Aging of vestibular function evaluated using correlational vestibular autorotation test

Hsieh LC, Lin HC, Lee GS

Clinical Interventions in Aging 2014, 9:1463-1469

Published Date: 3 September 2014

Effects of tafluprost treatment for 3 years in patients with normal-tension glaucoma

Inoue K, Tanaka A, Tomita G

Clinical Ophthalmology 2013, 7:1411-1416

Published Date: 9 July 2013

Clinical evidence and mechanistic basis for vildagliptin's effect in combination with insulin

Schweizer A, Foley JE, Kothny W, Ahrén B

Vascular Health and Risk Management 2013, 9:57-64

Published Date: 15 February 2013

Glimepiride: evidence-based facts, trends, and observations

Basit A, Riaz M, Fawwad A

Vascular Health and Risk Management 2012, 8:463-472

Published Date: 15 August 2012

Validity and reproducibility of a physical activity questionnaire for older adults: questionnaire versus accelerometer for assessing physical activity in older adults

Siebeling L, Wiebers S, Beem L, Puhan MA, ter Riet G

Clinical Epidemiology 2012, 4:171-180

Published Date: 16 July 2012

Reduced reward-related probability learning in schizophrenia patients

Yılmaz A, Simsek F, Gonul AS

Neuropsychiatric Disease and Treatment 2012, 8:27-34

Published Date: 5 January 2012

Clinical profile of hypertension at a University Teaching Hospital in Nigeria

Arthur C Onwuchekwa, Sunday Chinenye

Vascular Health and Risk Management 2010, 6:511-516

Published Date: 1 July 2010

Fifty years chlorpromazine: a historical perspective

Thomas A Ban

Neuropsychiatric Disease and Treatment 2007, 3:495-500

Published Date: 8 October 2007